Cash and cash equivalents

Tandy Leather Factory Announces Certain Second Quarter Operating Results and Settlement of Previously Disclosed Securities and Exchange Commission Matter

Retrieved on: 
Wednesday, July 21, 2021

FORT WORTH, Texas, July 21, 2021 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (Pink: TLFA) today reported certain preliminary financial information for its second quarter ended June 30, 2021.

Key Points: 
  • FORT WORTH, Texas, July 21, 2021 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (Pink: TLFA) today reported certain preliminary financial information for its second quarter ended June 30, 2021.
  • Total sales for the second quarter 2021 were up about 8% compared to the second quarter of 2019, despite operating 11 fewer stores.
  • As of June 30, 2021, the Company had$0.4 million of debt and $5.9 million of cash and cash equivalents.
  • The Company also announced that it has entered into a settlement with the U.S. Securities and Exchange Commission (the SEC).

Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021

Retrieved on: 
Wednesday, July 21, 2021

Patient screening is finished and enrollment is now expected to be completed in Q3 2021, with topline data anticipated approximately one year later.

Key Points: 
  • Patient screening is finished and enrollment is now expected to be completed in Q3 2021, with topline data anticipated approximately one year later.
  • As of June 30, 2021, cash and cash equivalents were EUR 36.9 million (USD 43.9 million), as compared to EUR 40.2 million (USD 49.4 million) at December 31, 2020.
  • Cash and cash equivalents were fully offset by financial liabilities (excluding IFRS16 impacts and derivative debts) as of June 30, 2021.
  • Cash and cash equivalents net of financial liabilities (excluding IFRS16 impacts and derivative debts) were EUR 17.1 million on December 31, 2020.

Nanobiotix Provides Second Quarter Operational and Financial Update

Retrieved on: 
Tuesday, July 20, 2021

Regulatory News:

Key Points: 
  • Nanobiotix did not generate any revenue during the second quarter of 2021.
  • Revenue for the second quarter and first half of 2020 amounted to 13.4k and 36.9k respectively.
  • Nanobiotix reported cash, cash equivalents, and short-term investments totaling 102.3 million as of June 30, 2021, compared to 107.1 million as of March 31, 2021.
  • Nanobiotix plans to report half-year financial results for the six-months ended June 30, 2021, including condensed consolidated financial statements for the period, on September 8, 2021.

Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

Retrieved on: 
Monday, July 19, 2021

This transaction, which eliminates substantially all of the Companys outstanding debt, preserves approximately $31.2 million in cash, including $3.2 million in future interest payments that would have been payable through November 1, 2023.

Key Points: 
  • This transaction, which eliminates substantially all of the Companys outstanding debt, preserves approximately $31.2 million in cash, including $3.2 million in future interest payments that would have been payable through November 1, 2023.
  • Robert Gagnon, Chief Financial Officer of Verastem Oncology, commented: This conversion of our 2020 Notes eliminates substantially all outstanding debt and provides us with greater financial flexibility, all while reducing future cash needs for interest payments and to repay the notes at maturity.
  • Verastem Oncology ended the first quarter 2021 with cash, cash equivalents and investments of $127.1 million.
  • Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

MarineMax Expands Financial Capacity

Retrieved on: 
Tuesday, July 13, 2021

The facility now provides MarineMax with $500 million of borrowing capacity, further increasing the Companys liquidity and financial flexibility for future growth.

Key Points: 
  • The facility now provides MarineMax with $500 million of borrowing capacity, further increasing the Companys liquidity and financial flexibility for future growth.
  • At June 30, 2021, the Company had financial capacity of over $329 million, consisting of cash and cash equivalents, along with available borrowings under its credit facilities.
  • Michael H. McLamb, Executive Vice President, Chief Financial Officer and Secretary of MarineMax, Inc. stated, Through both organic and acquisition related growth, we have significantly increased the size of MarineMax.
  • MarineMax provides finance and insurance services through wholly owned subsidiaries and operates MarineMax Vacations in Tortola, British Virgin Islands.

Exela Technologies Reports Significant Boost to Cash and Cash Equivalents to over $205 Million and Remains on Path to Deleverage

Retrieved on: 
Wednesday, July 7, 2021

As an initial step, Exela intends to target an annual debt service reduction of $25 million.

Key Points: 
  • As an initial step, Exela intends to target an annual debt service reduction of $25 million.
  • The higher liquidity will help us better leverage our tech enabled business services model by enabling us to fund our growth.
  • Furthermore, the targeted $25 million permanent reduction in annual debt service creates significant value to equity holders as the Company executes its strategic deleveraging.
  • As of June 30, 2021, the Company had over $205 million of cash and cash equivalents.

scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®

Retrieved on: 
Thursday, July 1, 2021

We are pleased with the outcome of our Type C meeting, and subsequent receipt of the meeting minutes, as this represents an important step forward as we continue to advance FUROSCIX toward potential commercialization, stated John Tucker, chief executive officer of scPharmaceuticals.

Key Points: 
  • We are pleased with the outcome of our Type C meeting, and subsequent receipt of the meeting minutes, as this represents an important step forward as we continue to advance FUROSCIX toward potential commercialization, stated John Tucker, chief executive officer of scPharmaceuticals.
  • The results, if positive, can potentially demonstrate significant cost savings from treating congestion in patients with heart failure with FUROSCIX outside of the hospital setting.
  • scPharmaceuticals ended the first quarter of 2021 with cash, cash equivalents, restricted cash and investments of $96.5 million.
  • FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.

IBI Group Delivers Exceptional Results with Net Profit Surging 151.5%

Retrieved on: 
Thursday, June 24, 2021

The Group maintained a strong financial position with cash and cash equivalents of approximately HK$87.1 million and no bank borrowings as at 31 March 2021.

Key Points: 
  • The Group maintained a strong financial position with cash and cash equivalents of approximately HK$87.1 million and no bank borrowings as at 31 March 2021.
  • Over the course of the year, the investments performed well and delivered impressive results with segmental profit reaching approximately HK$43.9 million.
  • Mr. Neil Howard, Chairman and CEO of IBI, said, "Although FY2021 was a year of unprecedented challenges, by implementing a sound tactical development strategy, IBI continued to deliver exceptional performance.
  • We are thrilled to see our net profit up 151.5% and to have launched our new subsidiaries.

Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, June 24, 2021

Appointed Joseph Young, MBA, as Senior Vice President of Finance and Chief Accounting Officer to oversee finance and accounting, administration, and corporate operations.

Key Points: 
  • Appointed Joseph Young, MBA, as Senior Vice President of Finance and Chief Accounting Officer to oversee finance and accounting, administration, and corporate operations.
  • During the first quarter 2021, net cash used in operating activities was $4.1 million, compared to $2.3 million for the same period last year.
  • Vera reported approximately $49.5 million in cash and cash equivalents as of March 31, 2021.
  • Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases.

Clairvest Reports Fiscal 2021 Fourth Quarter and Year End Results

Retrieved on: 
Tuesday, June 22, 2021

TORONTO, June 22, 2021 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2021 and material events which occurred subsequent to year end.

Key Points: 
  • TORONTO, June 22, 2021 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fourth quarter and year ended March 31, 2021 and material events which occurred subsequent to year end.
  • In addition, our acquisition entities held $66 million in cash and cash equivalents as at March 31, 2021 bringing total available cash to $345 million.
  • Net income for the fourth quarter was $14.8 million, or $0.98 per share.
  • The net income for the fourth quarter of fiscal 2021 reflects a net increase in the fair value of Clairvests investee companies and a corresponding increase in carried interest from the CEP Funds.